| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| 2821- | CUR, | Antioxidant curcumin induces oxidative stress to kill tumor cells (Review) |
| - | Review, | Var, | NA |
| 2979- | CUR, | GB, | Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death |
| - | in-vitro, | Lung, | H157 | - | in-vitro, | Lung, | H1299 |
| - | in-vitro, | GBM, | NA |
| 6239- | CUSP9, | The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy |
| - | in-vitro, | GBM, | NA |
| 9093- | CV, | Microalga Chlorella sp. extract induced apoptotic cell death of cholangiocarcinoma via AKT/mTOR signaling pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Liver, | HUH7 | - | in-vitro, | CCA, | KKU-100 |
| 9099- | CV, | Effect of a hot water extract of Chlorella vulgaris on proliferation of IEC-6 cells |
| - | in-vitro, | Nor, | IEC-6 |
| 7437- | CYN, | Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma |
| - | in-vitro, | Mye, | AMO1 | - | in-vivo, | Mye, | NA | - | in-vitro, | Mye, | KMS11 | - | in-vitro, | Mye, | JJN3 | - | in-vitro, | Mye, | MolP8 | - | in-vitro, | Mye, | L363 | - | in-vitro, | Mye, | H929 |
| 1871- | DAP, | Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth |
| - | in-vitro, | AML, | U937 | - | in-vivo, | AML, | NA |
| 1443- | Deg, | Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | BC, | BT549 |
| 1444- | Deg, | Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer |
| - | in-vitro, | GC, | MKN-28 |
| 1445- | Deg, | Deguelin--an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model |
| - | in-vivo, | lymphoma, | NA | - | in-vitro, | lymphoma, | NA |
| 1446- | Deg, | Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells |
| - | in-vitro, | BC, | 4T1 |
| 6675- | Deg, | Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 6674- | Deg, | Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway |
| - | in-vitro, | Lung, | H1975 |
| 6672- | Deg, | Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice |
| - | vitro+vivo, | CRC, | COLO205 | - | in-vitro, | CRC, | HCT116 |
| 6677- | Deg, | Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis |
| - | in-vitro, | NSCLC, | NA |
| 6705- | DFC, | Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases |
| - | Review, | Var, | NA |
| 6709- | DFC, | Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 |
| 1184- | DHA, | Syndecan-1-Dependent Suppression of PDK1/Akt/Bad Signaling by Docosahexaenoic Acid Induces Apoptosis in Prostate Cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 1854- | dietFMD, | How Far Are We from Prescribing Fasting as Anticancer Medicine? |
| - | Review, | Var, | NA |
| 1860- | dietFMD, | Chemo, | Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | 4T1 |
| 1844- | dietFMD, | Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment |
| - | Review, | Var, | NA |
| 2263- | dietMet, | Methionine Restriction and Cancer Biology |
| - | Review, | Var, | NA |
| 2269- | dietMet, | Mechanisms of Increased In Vivo Insulin Sensitivity by Dietary Methionine Restriction in Mice |
| - | in-vivo, | Nor, | NA |
| 8828- | DIM, | Induction of growth arrest and apoptosis in human breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27kip |
| - | in-vitro, | BC, | MCF-10AT | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | BT20 | - | in-vitro, | BC, | BT474 |
| 8853- | DIM, | Chemopreventive properties of 3,3′-diindolylmethane in breast cancer: evidence from experimental and human studies |
| - | Review, | Var, | NA |
| 8851- | DIM, | 3,3’-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs |
| - | Review, | Var, | NA |
| 8847- | DIM, | Studies on the mode of action of synthetic diindolylmethane derivatives against triple negative breast cancer cells |
| - | in-vitro, | BC, | NA |
| 8845- | DIM, | I3C, | 3,3′-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways |
| - | Review, | Var, | NA |
| 8844- | DIM, | I3C, | Unveiling the Multifaceted Pharmacological Actions of Indole-3-Carbinol and Diindolylmethane: A Comprehensive Review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 4987- | Dipy, | ATV, | Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination |
| - | in-vivo, | Nor, | NA |
| 6269- | DL, | Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells |
| - | in-vitro, | CRC, | LS174T |
| 6287- | DL, | D-Limonene Is a Potential Monoterpene to Inhibit PI3K/Akt/IKK-α/NF-κB p65 Signaling Pathway in Coronavirus Disease 2019 Pulmonary Fibrosis |
| - | in-vivo, | Covid, | NA |
| 6342- | DRE, | Mechanistic Study on the Inhibitory Effect of Dandelion Extract on Breast Cancer Cell Proliferation and Its Induction of Apoptosis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 6343- | DRE, | Dandelion root extract affects ESCC progression via regulating multiple signal pathways |
| - | vitro+vivo, | ESCC, | NA |
| 6348- | DRE, | New prospects in oncotherapy: bioactive compounds from Taraxacum officinale |
| - | Review, | Var, | NA |
| 6354- | DRE, | Taraxacum officinale L. in leukemia and lymphoma: current knowledge and prospects for horticulture |
| - | Review, | AML, | NA |
| 6359- | DRE, | Natural Health Products (NHP’s) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer; Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends |
| - | Review, | Var, | NA |
| 6360- | DRE, | Dandelion Seed Extract Affects Tumor Progression and Enhances the Sensitivity of Cisplatin in Esophageal Squamous Cell Carcinoma |
| - | in-vitro, | ESCC, | KYSE450 | - | in-vitro, | ESCC, | Eca109 |
| 5012- | DSF, | Cu, | Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems |
| - | Review, | Var, | NA |
| 1607- | EA, | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| - | Review, | GC, | NA |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1621- | EA, | The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art |
| - | Review, | Var, | NA |
| 1606- | EA, | Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells |
| - | in-vitro, | Colon, | HCT15 |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1610- | EA, | Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer |
| - | Review, | Cerv, | NA |
| 1618- | EA, | A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action |
| - | Review, | BC, | NA |
| 27- | EA, | Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice |
| - | in-vivo, | PC, | PANC1 |
| 3205- | EGCG, | The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2459- | EGCG, | Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis |
| - | in-vitro, | Tong, | Tca8113 | - | in-vitro, | Tong, | TSCCa |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:4 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid